摘要
目的:探讨奎硫平与阿立哌唑治疗首发精神分裂症的临床疗效与安全性。方法:将70例首发精神分裂症患者,随机分为奎硫平组35例,阿立哌唑组35例,疗程8周。采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)评定不良反应。结果:奎硫平组的治疗总有效率为85.7%,阿立哌唑组的治疗总有效率为82.9%,两组疗效差异无显著性(P>0.05)。结论:奎硫平与阿立哌唑治疗首发精神分裂症均有良好效果,不良反应均较轻。
Objective： To compare the efficacy and safety of quetiapine and aripiprazole in the treatment of first episode schizophrenia. Method ：70 cases of patients with schizophrenia were divided into two groups treated with quetiapine or aripiprazole respectively for 8 weeks. The positive and negative symptom scale（ PANSS） and treatment emergent symptoms effect scale （TESS） were used to evaluate the efficacy and adverse effect, respectively. Results ：The efficacy rates of quetiapine group was 85.7% after 8 weeks while that was 82.9% in aripiprazole group . There was no significant difference between the two groups of efficacy rates （ P 〉 0.05 ）. Conclusion ： Quetiapine is effective and safe as aripiprazole for the treatment of first episode schizophrenia and fewer side effects.
出处
《临床精神医学杂志》
2008年第3期191-192,共2页
Journal of Clinical Psychiatry
关键词
奎硫平
阿立哌唑
首发精神分裂症
quetiapine
aripiprazole
first episode schizophrenia
